M&A

August 9, 2021

iGaming Takes to the Sky 💸 🎈

The iGaming and sports betting industry are charging higher after two high-profile acquisitions. 💰 💰

Shares of the Roundhill Sports Betting & iGaming ETF ($BETZ) have increased 7% in the last week, ballooned by optimism surrounding $PENN and $DKNG‘s recent M&A deals. 🎈

On Thursday, Penn National Gaming made a bid to acquire sports betting platform theScore in a $2B deal. Penn, which owns a majority stake in Barstool Sports and its Barstool betting app, will pick up 4 million new daily active users. Many of theScore’s customers are in regions where Barstool Sportsbook is not currently offered, such as Colorado, Indiana, Iowa, New Jersey, and Canada.

This morning, DraftKings announced it would acquire Golden Nugget Online for $1.5B. The company offers iGaming in the United States, mostly through online casinos. With the deal, DraftKings will bring 5 million casino bettors into its orbit. 🚀 Investors weren’t initially sold on the acquisition’s value-add, but $GNOG CEO Tilman Feritta insists that iGaming customers are “worth seven times the value of a sports betting customer.”

Related Articles

Related Articles

UnitedHealth Drops Despite Beat

January 12, 2024

Both deals support the prospects for more consolidation and M&A in the betting and iGaming industry. The online betting M&A narrative is mirrored in other industries — companies sitting on large pots of money have been investing to diversify their businesses, capture new audiences, and expand their horizons. ☀️

$PENN‘s acquisition was well-received, boosting the stock +4.4%. $DKNG‘s acquisition was generally well-received, pushing the stock up 1.59% in the day. Shares of both future acquisitions — $SRC.CA & $GNOG — saw double-digit gains. 💪

Learn More About...

You Might Also Enjoy

Earnings

January 4, 2024

Self-Driving Vehicle Problems Mount

It’s been a rough time for the self-driving vehicle industry, with issues around GM’s Cruise unit renewing the regulatory spotlight on the space in late 2023. Unfortunately for investors betting on a quick turnaround, self-driving technology company Mobileye Global warned that it may take longer than anticipated. ⚠️

The company said its results this year will be impacted by customers clearing excess inventory for their books before placing new orders. It provided a preliminary 2024 operating loss between $378 and $468 million, much more significant than its preliminary 2023 operating loss of $33 to $39 million. Its 2024 revenue forecast of $1.83 to $1.96 billion also fell short of the $2.58 billion consensus view. 📊

Read It

M&A

January 8, 2024

Biotech Builds Buyout Momentum

It was another busy Monday of M&A activity in the biotech and healthcare space, with more expected during this week’s annual JPMorgan Healthcare Conference. Let’s quickly recap today’s deals. 📝

Johnson & Johnson will acquire cancer drug developer Ambrx Biopharma for $2 billion in cash. Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as “guided missiles” to directly target and kill cancer cells while limiting damage to healthy cells. 🎯

Read It

Company News

January 4, 2024

Peloton’s New Partnership

With Peloton’s turnaround strategy not yet bearing the fruit it had anticipated, the company continues to lean on partnerships to grow market share. For example, in September, the company entered a 5-year strategic partnership with Lulemon to bring its content to the athleisure brand’s exercise app. It also made Lululemon Peloton’s primary athletic apparel partner. 👟

It’s still too early to tell whether or not that cooperative effort is working, but management seems to think further initiatives like it will help boost revenues. As a result, it’s partnering with TikTok to bring short-form fitness videos and other content to the social media platform.

Read It

More in   M&A

View All

M&A

February 5, 2024

Another Day Of M&A

As usual, it was another busy Monday of mergers and acquisitions. Let’s recap the biggest deals. 📝

First, Danish pharmaceutical giant Novo Nordisk’s parent company is buying drug manufacturer Catelent for $16.5 billion to help boost the supply of popular weight loss injection Wegovy and diabetes shot Ozempic. Novo Nordisk will then buy three of Catalent’s manufacturing sites from its parent company for $11 billion, giving it further access to the fill-finish part of its Wegovy product. 🏭

Read It

M&A

May 5, 2022

Peloton Searches for Its Knight in Shining Armor

After a punishing year for the at-home fitness company Peloton, the company is reportedly looking to sell nearly a fifth of its business in an effort to absolve themselves of near-term financial headwinds.

According to the Wall Street Journal, the company is perusing the catalog of industry giants and private equity firms alike in their search. Such a deal might not pan out, but new money might help the downtrodden pandemic-era giant find its way in a post-pandemic world.

Read It

M&A

October 23, 2023

A Day Of M&A Madness

As is usually the case, there was a lot of weekend news regarding mergers, acquisitions, partnerships, and more. So, let’s review the biggest ones. 👇

First up is oil giant Chevron buying its U.S. rival Hess for $53 billion, marking the second-largest deal in decades. The all-cash deal comes just weeks after Exxon Mobil purchased Pioneer Natural Resources for $59.5 billion to expand its reach in the Permian Basin. It also purchased Denbury this summer for $4.9 billion.

Read It

M&A

April 25, 2022

For Musk, It’s “Funding Secured” On Twitter Buyout

An 11-day long fight between the world’s richest person and one of the most beloved social media platforms has come to a close: Elon Musk is buying Twitter. 

The deal’s terms haven’t changed — Musk will pay $44 billion, that’ll be $54.20/share — to acquire the site. Twitter originally didn’t take Musk’s deal seriously. In fact, the Board even imposed a “poison pill” to prevent Musk from acquiring more than 15% of the company.

Read It